Outcome of Repeated Thrombolysis in Debrecen Thrombolysis Database

Klára Fekete, Sándor Márton, L. Csiba, I. Fekete

Research output: Contribution to journalArticle

Abstract

Introduction Recombinant tissue plasminogen activator (rtPA) is an efficient therapy of acute ischemic stroke. The risk of a recurrent ischemic stroke is high. This prospective single center study aimed to assess whether or not the repeated rtPA treatment is beneficial for acute stroke patients. Methods All thrombolysed patients' data at the Department of Neurology, University of Debrecen have been recorded in the Debrecen Thrombolysis Database (DTD) since 2004. We identified 21 patients with repeated thrombolysis. Stroke severity by the NIH stroke scale score (NIHSSS) and imaging findings by the Alberta Stroke Programme Early CT Score were evaluated on admission and 1 day later. The modified Rankin Scale score at 3 months and case fatality at 1 year were evaluated. We compared the first and second thrombolyses, and we screened for bleeding and allergic reactions to determine safety. Results Within the 27-month median time, 18 patients were thrombolysed twice, with complete follow-up. In recurrent stroke patients, diabetes mellitus, congestive heart failure, and anticoagulation were more common. Admission cholesterol levels were decreased. After the first and second treatments, 24-hour NIHSSS were 3 (1;6) and 7 (1;10), respectively. At 3 months, good outcome was significantly higher after the first treatment than those of DTD, with no differences between the 2 attempts. There was little difference in 3-month and 1-year outcomes, regardless of laterality—ipsilateral or contralateral hemisphere—in recurrent strokes. One patient had nonsymptomatic intracranial bleeding after repeated rtPA treatment. Discussion Recurrent rtPA treatment may be safe and effective in patients who have mild or moderate residual symptoms after the index stroke.

Original languageEnglish
Pages (from-to)132-138
Number of pages7
JournalJournal of Stroke and Cerebrovascular Diseases
Volume26
Issue number1
DOIs
Publication statusPublished - Jan 1 2017

Fingerprint

Stroke
Databases
Tissue Plasminogen Activator
Therapeutics
Hemorrhage
Alberta
Neurology
Diabetes Mellitus
Hypersensitivity
Heart Failure
Cholesterol
Safety

Keywords

  • outcome
  • Recurrent ischemic stroke
  • repeated thrombolysis
  • symptomatic intracranial hemorrhage

ASJC Scopus subject areas

  • Surgery
  • Rehabilitation
  • Clinical Neurology
  • Cardiology and Cardiovascular Medicine

Cite this

Outcome of Repeated Thrombolysis in Debrecen Thrombolysis Database. / Fekete, Klára; Márton, Sándor; Csiba, L.; Fekete, I.

In: Journal of Stroke and Cerebrovascular Diseases, Vol. 26, No. 1, 01.01.2017, p. 132-138.

Research output: Contribution to journalArticle

@article{9d0ae2b738e7487093a2bf9d6ed02acd,
title = "Outcome of Repeated Thrombolysis in Debrecen Thrombolysis Database",
abstract = "Introduction Recombinant tissue plasminogen activator (rtPA) is an efficient therapy of acute ischemic stroke. The risk of a recurrent ischemic stroke is high. This prospective single center study aimed to assess whether or not the repeated rtPA treatment is beneficial for acute stroke patients. Methods All thrombolysed patients' data at the Department of Neurology, University of Debrecen have been recorded in the Debrecen Thrombolysis Database (DTD) since 2004. We identified 21 patients with repeated thrombolysis. Stroke severity by the NIH stroke scale score (NIHSSS) and imaging findings by the Alberta Stroke Programme Early CT Score were evaluated on admission and 1 day later. The modified Rankin Scale score at 3 months and case fatality at 1 year were evaluated. We compared the first and second thrombolyses, and we screened for bleeding and allergic reactions to determine safety. Results Within the 27-month median time, 18 patients were thrombolysed twice, with complete follow-up. In recurrent stroke patients, diabetes mellitus, congestive heart failure, and anticoagulation were more common. Admission cholesterol levels were decreased. After the first and second treatments, 24-hour NIHSSS were 3 (1;6) and 7 (1;10), respectively. At 3 months, good outcome was significantly higher after the first treatment than those of DTD, with no differences between the 2 attempts. There was little difference in 3-month and 1-year outcomes, regardless of laterality—ipsilateral or contralateral hemisphere—in recurrent strokes. One patient had nonsymptomatic intracranial bleeding after repeated rtPA treatment. Discussion Recurrent rtPA treatment may be safe and effective in patients who have mild or moderate residual symptoms after the index stroke.",
keywords = "outcome, Recurrent ischemic stroke, repeated thrombolysis, symptomatic intracranial hemorrhage",
author = "Kl{\'a}ra Fekete and S{\'a}ndor M{\'a}rton and L. Csiba and I. Fekete",
year = "2017",
month = "1",
day = "1",
doi = "10.1016/j.jstrokecerebrovasdis.2016.08.044",
language = "English",
volume = "26",
pages = "132--138",
journal = "Journal of Stroke and Cerebrovascular Diseases",
issn = "1052-3057",
publisher = "W.B. Saunders Ltd",
number = "1",

}

TY - JOUR

T1 - Outcome of Repeated Thrombolysis in Debrecen Thrombolysis Database

AU - Fekete, Klára

AU - Márton, Sándor

AU - Csiba, L.

AU - Fekete, I.

PY - 2017/1/1

Y1 - 2017/1/1

N2 - Introduction Recombinant tissue plasminogen activator (rtPA) is an efficient therapy of acute ischemic stroke. The risk of a recurrent ischemic stroke is high. This prospective single center study aimed to assess whether or not the repeated rtPA treatment is beneficial for acute stroke patients. Methods All thrombolysed patients' data at the Department of Neurology, University of Debrecen have been recorded in the Debrecen Thrombolysis Database (DTD) since 2004. We identified 21 patients with repeated thrombolysis. Stroke severity by the NIH stroke scale score (NIHSSS) and imaging findings by the Alberta Stroke Programme Early CT Score were evaluated on admission and 1 day later. The modified Rankin Scale score at 3 months and case fatality at 1 year were evaluated. We compared the first and second thrombolyses, and we screened for bleeding and allergic reactions to determine safety. Results Within the 27-month median time, 18 patients were thrombolysed twice, with complete follow-up. In recurrent stroke patients, diabetes mellitus, congestive heart failure, and anticoagulation were more common. Admission cholesterol levels were decreased. After the first and second treatments, 24-hour NIHSSS were 3 (1;6) and 7 (1;10), respectively. At 3 months, good outcome was significantly higher after the first treatment than those of DTD, with no differences between the 2 attempts. There was little difference in 3-month and 1-year outcomes, regardless of laterality—ipsilateral or contralateral hemisphere—in recurrent strokes. One patient had nonsymptomatic intracranial bleeding after repeated rtPA treatment. Discussion Recurrent rtPA treatment may be safe and effective in patients who have mild or moderate residual symptoms after the index stroke.

AB - Introduction Recombinant tissue plasminogen activator (rtPA) is an efficient therapy of acute ischemic stroke. The risk of a recurrent ischemic stroke is high. This prospective single center study aimed to assess whether or not the repeated rtPA treatment is beneficial for acute stroke patients. Methods All thrombolysed patients' data at the Department of Neurology, University of Debrecen have been recorded in the Debrecen Thrombolysis Database (DTD) since 2004. We identified 21 patients with repeated thrombolysis. Stroke severity by the NIH stroke scale score (NIHSSS) and imaging findings by the Alberta Stroke Programme Early CT Score were evaluated on admission and 1 day later. The modified Rankin Scale score at 3 months and case fatality at 1 year were evaluated. We compared the first and second thrombolyses, and we screened for bleeding and allergic reactions to determine safety. Results Within the 27-month median time, 18 patients were thrombolysed twice, with complete follow-up. In recurrent stroke patients, diabetes mellitus, congestive heart failure, and anticoagulation were more common. Admission cholesterol levels were decreased. After the first and second treatments, 24-hour NIHSSS were 3 (1;6) and 7 (1;10), respectively. At 3 months, good outcome was significantly higher after the first treatment than those of DTD, with no differences between the 2 attempts. There was little difference in 3-month and 1-year outcomes, regardless of laterality—ipsilateral or contralateral hemisphere—in recurrent strokes. One patient had nonsymptomatic intracranial bleeding after repeated rtPA treatment. Discussion Recurrent rtPA treatment may be safe and effective in patients who have mild or moderate residual symptoms after the index stroke.

KW - outcome

KW - Recurrent ischemic stroke

KW - repeated thrombolysis

KW - symptomatic intracranial hemorrhage

UR - http://www.scopus.com/inward/record.url?scp=84995777964&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84995777964&partnerID=8YFLogxK

U2 - 10.1016/j.jstrokecerebrovasdis.2016.08.044

DO - 10.1016/j.jstrokecerebrovasdis.2016.08.044

M3 - Article

C2 - 27671096

AN - SCOPUS:84995777964

VL - 26

SP - 132

EP - 138

JO - Journal of Stroke and Cerebrovascular Diseases

JF - Journal of Stroke and Cerebrovascular Diseases

SN - 1052-3057

IS - 1

ER -